HomeAustraliaHeidi Expands AI Capabilities with UK Healthtech Acquisition

Heidi Expands AI Capabilities with UK Healthtech Acquisition

Heidi Expands AI Capabilities with UK Healthtech Acquisition

Doctor-focused clinical notes startup Heidi has acquired UK-based AI healthcare platform Automedica as it increases its focus on artificial intelligence. The financial details of the deal were not shared.

The Melbourne-based company started as an AI scribe for general practitioners (GPs) and has already supported over 100 million clinical interactions worldwide. Now, it is expanding into a broader range of AI healthcare products.

Last year, Heidi raised $125 million in venture funding, including a $98 million Series B round in October at a $703 million valuation, along with a $27 million Series A extension earlier in the year.

After acquiring Automedica, Heidi launched two new AI tools: Heidi Evidence, which helps doctors stay updated with the latest medical knowledge, and Heidi Comms, which helps healthcare teams manage patient communication and care plans more efficiently.

Heidi Evidence is partly built using Anthropic’s Claude AI models, providing real-time clinical insights during doctor consultations, combined with Automedica’s evidence-based AI system.

Heidi cofounder and CEO Dr Thomas Kelly said the strategic acquisition accelerates Heidi’s technical and regulatory capabilities and its UK presence, as well as giving the startup access to the MHRA AI Airlock, a regulatory sandbox for healthcare AI.

“We believe that for AI to be a true care partner, the integrity of its evidence must be non-negotiable,” he said.

“As we see more general-purpose AI platforms like OpenAI move toward ad-supported models, consumers are rightly concerned about hidden influence.”

Dr Kelly said that in a healthcare setting, that concern becomes paramount.

“Bringing transparent, clinical-grade insights into the room makes it easier to deliver quality care, but that information must be free from the ambiguity of commercial influence,” he said.

“By committing to Evidence being ad-free and independent, we ensure clinicians can stay present with their patients, knowing their decision-making is built on pure clinical rigour, not a business model.”

Read More- Astelia raises $25 million Series A round led by Index Ventures

- Advertisement -
RELATED ARTICLES
- Advertisment -

Most Popular